PMEF
VERV

Point72 Middle East FZE’s Verve Therapeutics VERV Stock Holding History

Point72 Middle East FZE’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-16,498
Closed -$238K – 2086
2023
Q1 		$238K Buy
+16,498
New +$323K 0.01% 897

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Point72 Middle East FZE's VERV Position: Q2 2023 in Review

Point72 Middle East FZE sold out of Verve Therapeutics (VERV) in Q2 2023, closing a stake of 16,498 shares — an estimated $238K sold.

Point72 Middle East FZE first reported a position in VERV in Q1 2023 and held it in 1 quarter. The position peaked at $238K in Q1 2023. 121 funds tracked by Wall St. Rank hold VERV as of Q2 2023.

  • Point72 Middle East FZE reported no remaining Verve Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 16,498 Verve Therapeutics shares in Q2 2023, an estimated $238K.
  • Point72 Middle East FZE first reported a position in Verve Therapeutics in Q1 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Verve Therapeutics position peaked at $238K in Q1 2023.
  • 121 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.